Marker Therapeutics Awarded $2 Million Grant from US FDA to Support Marker’s Phase II ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics, Inc. announced that the company has been awarded a $2 million grant from the US FDA Orphan Products Grants program to support its Phase II ARTEMIS trial of its lead multi-tumor-associated antigen T cell product candidate, MT-401, in patients with post-transplant acute myeloid leukemia (AML).